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Cannabinoid receptors are able to couple to different families of G proteins when
activated by an agonist drug. It has been suggested that different intracellular
responses may be activated depending on the ligand. The goal of the present study
was to characterize the pattern of G protein subunit stimulation triggered by three
different cannabinoid ligands, 91 -THC, WIN55212-2, and ACEA in mouse brain cortex.
Stimulation of the [35S]GTPγS binding coupled to specific immunoprecipitation with
antibodies against different subtypes of G proteins (Gαi1, Gαi2, Gαi3, Gαo, Gαz, Gαs,
Gαq/11, and Gα12/13), in the presence of 91 -THC, WIN55212-2 and ACEA (submaximal
concentration 10 µM) was determined by scintillation proximity assay (SPA) technique
in mouse cortex of wild type, CB1 knock-out, CB2 knock-out and CB1/CB2 double
knock-out mice. Results show that, in mouse brain cortex, cannabinoid agonists are
able to significantly stimulate not only the classical inhibitory Gαi/o subunits but also
other G subunits like Gαz, Gαq/11, and Gα12/13. Moreover, the specific pattern of G
protein subunit activation is different depending on the ligand. In conclusion, our results
demonstrate that, in mice brain native tissue, different exogenous cannabinoid ligands
are able to selectively activate different inhibitory and non-inhibitory Gα protein subtypes,
through the activation of CB1 and/or CB2 receptors. Results of the present study may
help to understand the specific molecular pathways involved in the pharmacological
effects of cannabinoid-derived drugs.
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INTRODUCTION
During the last decade a wide number of studies have focused on the potential involvement
of the endocannabinoid system in a variety of psychiatric and neurological disorders. The
putative psychoactive ingredient of Cannabis sativa (marijuana plant), 19-tetrahydrocannabinol
(19-THC), as well as the endogenous cannabinoids anandamide (arachidonoyl ethanolamide) and
Abbreviations: 2-AG, 2- arachidonoylglycerol; ACEA, arachidonyl-2-chloroethylamide; CB1−/−, CB1 knock-out mice;
CB2−/−, CB2 knock-out mice; CB1−/−/CB2−/−, CB1 and CB2 double knock-out mice; P1, pellet fraction; P2, membrane
enriched fraction; PVT, polyvinyltoluene; RT, room temperature; SDS, sodium dodecyl sulfate; SPA, scintillation proximity
assay; TBS, tris-buffered saline; WT, wild type;19-THC,19-tetrahydrocannabinol.
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2-arachidonoylglycerol (2-AG) act primarily through
cannabinoid CB1 and CB2 receptors. These cannabinoid
receptors are GPCRs mostly coupled to Gi/o proteins (Howlett
et al., 2002). The CB1 receptor is mainly distributed in the
CNS, particularly in cortex, basal ganglia, hippocampus, and
cerebellum (Mackie, 2005; De Jesus et al., 2006) and generally
acts presinaptically inhibiting the release of neurotransmitters.
CB2 receptors are expressed at much lower levels in the CNS
compared with CB1 receptors (reviewed in Atwood and Mackie,
2010). As Gi/o coupled GPCRs, CB1 and CB2 receptors inhibit
adenylyl cyclase, but moreover, both receptors are able to
activate MAPK, inhibit voltage gated Ca2+ channels and activate
inwardly rectifying K+ channels (Childers et al., 1993).
The activation of CB1 receptor in the brain leads to
the modulation of neuronal excitability, which may be in
part responsible of the psychoactive effects of exogenous
cannabinoids. In this context, a considerable amount of studies
have been performed in order to elucidate the effects of
cannabinoids (natural or synthetics) in the development of
mental alterations, such as addiction, cognitive deficits, anxiety
or psychosis. Importantly, different or opposite behavioral effects
have been observed after the administration of 19-THC or
synthetic cannabinoid ligands (Fattore et al., 2003; Panagis et al.,
2014; Rubino and Parolaro, 2016). It has been demonstrated
that for most G protein-coupled receptors, distinct agonists can
differentially regulate several signaling pathways through the
same receptor by a selective activation of different intracellular
effectors. This is a mechanism known as functional selectivity or
biased agonism. In this way, cannabinoid receptors have been
demonstrated to be capable of coupling to different families
of G proteins and/or to beta-arrestin when activated by an
agonist drug suggesting that different intracellular responses
may be activated depending on the ligand (Glass and Northup,
1999; Bosier et al., 2010). For instance, for the CB1 receptor
has been reported that, whereas 2-AG and WIN55,212 have
little preference for inhibition of cAMP and phosphorylation of
ERK1/2, anandamide and CP55940 were biased toward cAMP
inhibition (Khajehali et al., 2015). Moreover, in a recent study
Dhopeshwarkar and Mackie (2016) demonstrated that CB2
receptor ligands display strong and varied functional selectivity
at canonical (inhibition of adenylyl cyclase) and non-canonical
(arrestin recruitment) pathways. Moreover, the intracellular
signaling activated by a receptor depends on the cellular system
where it is expressed, which may vary across different neuronal
environments. In this context, it has been demonstrated that
opioid and cannabinoid receptors function through the same
pool of G proteins when they are co-transfected, whereas in
cells endogenously expressing these receptors signaling occurs
through distinct pools of G proteins (Shapira et al., 2000). Thus,
this fact should be taken into consideration when interpreting
results acquired in artificially transfected cells vs. native biological
systems.
To our knowledge, no study has compared G protein signaling
by different cannabinoid drugs in native brain tissue. Thus, in the
current study, we performed [35S]GTPγS scintillation proximity
assay (SPAs) coupled with the use of specific antibodies against
different Gα protein subunits to evaluate the functional selectivity
of different cannabinoid ligands by activating CB1 and/or CB2
cannabinoid receptors in mouse brain cortex.
MATERIALS AND METHODS
Animal Procedures
Adult C57BL/6J (WT), CB1 knock-out (CB1−/−) (Marsicano
et al., 2002), CB2 knock-out (CB2−/−) (Buckley et al., 2000),
and CB1/CB2 double knock-out (CB1−/−/CB2−/−) mice were
used in this study. Animals (males, aged 7–8 weeks-old) were
housed (6–8 animals per cage) in standard cages under controlled
conditions of temperature (23 + 1◦C) and photoperiod
(light/dark cycle 14 h: 10 h) and free access to standard rodent
chow and water.
Animal Welfare and Ethical Statements
All experimental procedures using mice were performed in
accordance with the European Directive for the Protection
of Vertebrate Animals used for experimental and Other
Scientific Purposes (European Union Directive #86/606/EEC)
and approved by the Ethics Committees for Animal Welfare
of the University of the Basque Country (UPV/EHU) permit
number CEBA1882011 and by the Institutional Review Board
(INIA), permit number CEEA2012/021.
Rationale for Choice of Cannabinoid
Ligands
In the present study, we decided to investigate the effects of
three different cannabinoid ligands. 19-THC was chosen for
being the main psychoactive component of marijuana plant
and the putative responsible of the development of mental
disorders in humans. WIN55212-2, a synthetic cannabinoid
structurally different from 19-THC, is a potent, non-selective
CB1/CB2 receptor agonist that is frequently used in the studies
that try to elucidate the effects of Cannabis in the brain.
Finally, we wanted to study a ligand structurally similar to
endogenous cannabinoids, such as the synthetic anandamide
analog arachidonyl-2-chloroethylamide (ACEA). O-2050 was
chosen as a neutral cannabinoid antagonist. O-2050 has been
proved to be a neutral CB1 receptor antagonist in several studies
(Canals and Milligan, 2008; Hudson et al., 2010; Brents et al.,
2011; Wiley et al., 2011), with quite similar affinity for CB1 and
CB2 receptors. Although, there is some data in the literature
suggesting its activity as inverse or even partial agonist at
CB1 receptors in various tissues (Makwana et al., 2010; Wiley
et al., 2011) in a previous work of our group, we showed that
O-2050 has no effect over [35S]GTPγS binding and behaves as an
antagonist blocking WIN55212-2-mediated activation (Erdozain
et al., 2012) (Figure 1).
Rationale for Choice of G Protein α
Subunit Subtypes
In the present study, we decided to investigate the ability of
cannabinoid receptors to activate different G proteins subtype.
We chose at least one G protein subtype representative of each
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FIGURE 1 | Chemical structure of the different cannabinoid ligands used. Representative scheme of the chemical structure of the different cannabinoid
ligands used in this study (19-tetrahydrocannabinol (19-THC), WIN55212-2, arachidonyl-2-chloroethylamide (ACEA) and O-2050).
main G protein family and mainly focusing in the inhibitory G
proteins for being the cannabinoid canonical pathway (Figure 2).
Mouse Brain Cortex Membrane
Homogenates Preparation
After sacrifice by cervical dislocation, the brains were
rapidly removed, cortices dissected and fresh frozen, and
stored immediately at −80◦C until use. Preparation of
membrane enriched fraction (P2 fraction) was performed
as previously described (Gonzalez-Maeso et al., 2000) with minor
modifications. Mouse brain cortex samples (approximately
200 mg) from seven mice each time were thawed at 4◦C and
homogenized with a glass/teflon grinder (IKA labortechnik,
Satufen, Germany) (10 strokes at maximum speed) in 30
volumes of homogenization buffer (50 mM Tris-HCl (Invitrogen,
Barcelona, Spain), 1 mM EGTA (Sigma-Aldrich, St. Louis, MO,
USA), 3 mM MgCl2 (Sigma-Aldrich, St. Louis, MO, USA) and
1 mM DTT (Invitrogen, Barcelona, Spain); pH 7.4; supplemented
with 250 mM sucrose (Panreac Química S.A.U, Barcelona, Spain).
The homogenates were centrifuged at 1,100 × g for 10 min at
4◦C (Sorvall RC-5C centrifuge, SM-24 rotor; FisherScientific,
Madrid, Spain). The pellets (P1 fraction) were discarded and the
supernatants were then recentrifuged at 40,000 × g for 10 min
(4◦C). The resultant pellets were resuspended in 20 volumes of
fresh cold centrifugation buffer (50 mM Tris-HCl, 1 mM EGTA,
3 mM MgCl2 and 1 mM DTT; pH 7.4) with a glass stick and
recentrifuged at 40,000 × g for 10 min (4◦C). The obtained
pellets were then resuspended in five volumes of centrifugation
buffer. Protein content was determined by the method of
Bradford with BSA (Sigma-Aldrich R©, St. Louis, MO, USA) as
standard. Linear regression analysis and extrapolation of the data
were carried out with GraphPad Prism 5 R© software (GraphPad
Software, Inc., San Diego, CA, USA). Finally, aliquots of 0.5, 1,
and 2 mg were then centrifuged at 21,000× g (Eppendorf 5810R
centrifuge; Eppendorf, Madrid, Spain) during 15 min at 4◦C. The
supernatant layer was carefully discarded and the pellets stored
at−80◦C until assay.
Antibody-Capture [35S]GTPγS
Scintillation Proximity Assay (SPA)
Specific activation of different subtypes of Gα proteins was
determined using a homogeneous protocol of [35S]GTPγS
SPA coupled with the use of specific antibodies essentially as
previously described (Erdozain et al., 2012). [35S]GTPγS binding
was performed in 96-well Isoplates (PerkinElmer Life Sciences,
Maanstraat, Germany) and in a final volume of 200 ml containing
1 mM EGTA, 3 mM MgCl2, 100 mM NaCl, 0.2 mM DTT,
50 mM Tris-HCl at pH 7.4, 0.4 nM [35S]GTPγS, 15 µg of
protein per well, and different concentrations of GDP depending
on the Gα subunit subtype tested. At the end of the 2 h
incubation period (30◦C), 20 µl of Igepal 1% + SDS 0.1%
were added to each well, and plates were incubated at 22◦C
for 30 min with gentle agitation. Specific antibody for the Gα
subunit of interest was then added to each well before an
additional 90 min RT incubation period (the antibodies and
dilutions employed are described in Table 1). Polyvinyltoluene
(PVT) SPA beads coated with protein A (PerkinElmer, S.L., Tres
Cantos, Madrid, Spain) were then added (0.75 mg of beads
per well), and plates were incubated for 3 h at RT with gentle
agitation. Finally, plates were centrifuged (5 min at 1000 × g),
and bound radioactivity was detected on a MicroBeta TriLux
scintillation counter (PerkinElmer S.L., Tres Cantos, Madrid,
Spain). In order to test their effect on the [35S]GTPγS binding
to the different Gα subunit subtypes, a single submaximal
concentration of the drugs (10 µM) 19-THC, WIN55212-2,
ACEA and/or O-2050, was used. This submaximal concentration
was chosen as previously reported (Erdozain et al., 2012) in
our previous experimental assays in which we established the
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FIGURE 2 | G protein signaling pathways. Representative scheme of the signaling pathways linked to each G protein evaluated in this study.
TABLE 1 | Antibodies, dilutions, and GDP concentrations employed in the [35S]GTPγS scintillation proximity assays.
Target Description Commercial firm Catalog # [GDP] (µM) Ab dilution
Gαi1 Mouse monoclonal anti-Gαi1 Santa Cruz sc-56536 100 1:20
Gαi2 Rabbit polyclonal anti-Gαi2 Santa Cruz sc-7276 50 1:20
Gαi3 Rabbit polyclonal anti-Gαi3 Santa Cruz sc-262 200 1:30
Gαo Mouse monoclonal anti-Gαo BIOMOL SA-280 50 1:75
Gαz Rabbit polyclonal anti-Gαz Santa Cruz sc-388 100 1:20
Gαs Rabbit polyclonal anti-Gαs Santa Cruz sc-383 100 1:20
Gαq/11 Rabbit polyclonal anti-Gαq/11 Santa Cruz sc-392 50 1:20
Gα12/13 Rabbit polyclonal anti-Gα12/13 Santa Cruz sc-28588 100 1:20
standard conditions for this assays. This concentration is the
one which give us binding values around the Emax for any
drug and subunit subtype combination studied (Supplementary
Figure S1). Non-specific binding was defined as the remaining
[35S]GTPγS binding in the presence of 10 µM unlabelled
GTPγS.
Western Blot
For Western blot experiments, membrane enriched fraction
(P2 fraction) pellets from mouse brain tissue (cortex)
were resuspended in TBS, reaching a concentration of
4 mg protein/ml. Commercial Laemmli 2x (95%) and β-
mercaptoethanol (5%) (Sigma-Aldrich R©, St. Louis, MO,
USA) were added to each sample, reaching a final protein
concentration of 2 mg/ml. Finally, all the samples were heated
at 95◦C for 5 min in a Thermoblock (Biometra, Goettingen,
Germany) and kept at −20◦C until assay. Electrophoresis
was carried out in SDS polyacrylamide gels, composed
of 5% stacking (0.5 M Tris-HCl, pH 6.8, 10% SDS) and
12% resolving (1.5 M Tris-HCl, pH 8.8, 10% SDS) gels,
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using a miniprotean system (Bio-Rad Laboratories). Equal
protein loading in the gel was verified by simultaneous
immunodetection of β-actin (mouse monoclonal antibody
anti-β-actin, Sigma Biosciences, St. Louis, MO, USA) with the
different Gα subunit subtypes. Proteins were then transferred to
nitrocellulose membranes (1 h, 0.3 A) using an electrophoretic
transfer system (Bio-Rad Laboratories). The non-specific
binding sites in the membranes were blocked for 1 h at
RT in blocking solution (3% non-fat dry milk, pH = 7.4
in PBS). Membranes were incubated overnight at 4◦C in
incubation buffer (3% non-fat dry milk + 0.1% Tween-20
in PBS) containing the appropriate dilution of the specific
primary anti-Gα subunit antibody. Antibody specificity, as
previously described in the literature (Gettys et al., 1994;
Valdizan et al., 2010), was confirmed in our experimental
conditions by Western blot (data not shown). Membranes
were washed with PBS and incubated for 1 h at RT and
constant agitation with the fluorescent conjugated secondary
antibodies (Alexa Fluor R© 680 and/or IRDye 800 conjugated
antibodies) suitable diluted in incubation buffer. Finally,
membranes were rewashed with PBS and immunoreactivity was
detected and quantified using the Odyssey Infrared Imaging
System (LI-COR Biosciences, Lincoln, NE, USA) and Odyssey
Software. Broad-Range pre-stained SDS-PAGE molecular weight
standard (Bio-Rad Laboratories, Hercules, CA, USA) was
used.
Data Analysis and Statistical Procedures
Data were analyzed with GraphPad PrismTM 5.01 software.
In order to allow better interpretation of the data, specific
binding obtained from [35S]GTPγS SPAs were transformed
to percentage of basal binding (binding values observed in
the absence of any exogenous drug) obtained for each Gα
protein subunit studied. The statistical comparison of the SPA
results was carried out by a two-tailed one sample Student’s
t-test with a significance level of p < 0.05. Immunodensity
data obtained from Western blotting assays were transformed
to percentage of the control, being the control the mean
of immunodensities obtained for WT mice. The statistical
comparison of the Western blot results was carried out
by a one-way ANOVA test, followed by Dunnet’s post
hoc test for multiple comparisons, with a significance level
of p < 0.05. All data are expressed as mean ± SEM
values.
Materials
[35S]GTPγS (4625 × 1010 Bq/mmol) was purchased from
PerkinElmer Life Sciences (Maanstraat, Germany). Tetrahydro-
cannabinol (19-THC) was purchased from THCPharm GmbH
(Frankfurt, Germany); WIN55212-2 and GTPγS were purchased
from Sigma-Aldrich (St. Louis, MO, USA); Arachidonyl-
2-chloroethylamide ACEA and O-2050 were from Tocris
Bioscience (Bristol, UK). All other chemical reagents were of
analytical quality and were purchased from Merck (Darmstadt,
Germany) or Sigma-Aldrich (St. Louis, MO, USA).
RESULTS
Effects of 19-THC, WIN55212-2, and
ACEA on G Protein Activation in Mouse
Brain Membranes
Cannabinoid receptor ligands were used for the characterization
of the functional coupling of cannabinoid receptors to the
different G protein α subunit subtypes (Gαi1, Gαi2, Gαi3, Gαo,
Gαz, Gαs, Gαq/11, and Gα12/13) in mouse brain tissue. First,
we investigated which Gα subunit subtypes were activated by
the natural cannabinoid 19-THC (10 µM) in mouse brain
cortex membrane homogenates (Figure 3A). As expected, we
found that 19-THC was able to significantly activate several
classical AC inhibitory subunits, as Gαi1 (113 ± 3%), Gαo
(110 ± 2%), and Gαz (113 ± 5%), while exerted no effect on
Gαi2 or Gαi3. 19-THC was also able to activate the Gαq/11
subunit (118 ± 5%). However, no changes were observed
when we studied AC stimulatory subunit Gαs and the RhoA
activator Gα12/13 subunit. To further test if these effects of 19-
THC were cannabinoid-receptor mediated, the same assays were
carried out in the presence of a putative neutral antagonist
of the CB1 receptor, O-2050. In all cases, the activation of
these G protein subunits was blocked when membranes were
co-incubated with the cannabinoid antagonist O-2050. Next,
we investigated the effects on G protein subunit activation
induced by the synthetic cannabinoid agonist WIN55212-2
(Figure 3B). We found that WIN55212-2 significantly increased
the binding of [35S]GTPγS to the all the inhibitory subunits
Gαi1 (129 ± 6%), Gαi3 (129 ± 5%), Gαo (120 ± 4%)
and Gαz (134 ± 6%), except Gαi2. WIN55212-2 was also
able to activate the Gαq/11 subunit (131 ± 7%), but not
the AC stimulatory subunit Gαs. Surprisingly, WIN55212-2
was also able to significantly stimulate the RhoA activator
Gα12/13 (130 ± 4%). In the same way as previously described
for 19-THC, the activation of these G protein subunits by
WIN55212-2 was always blocked by the co-incubation with
the cannabinoid antagonist O-2050, except for the case of
Gαz (106 ± 1%). Finally, we investigated the effect of the
synthetic anandamide analog ACEA on G protein subunit
activation in mouse brain tissue (Figure 3C). When evaluating
the classical AC inhibitory subunits, we found that ACEA
stimulated Gαi1 (121 ± 4%), Gαi3 (120 ± 5%), and Gαo
(116± 4%). However, as occurred with19-THC and WIN55212-
2, no stimulation was observed in Gαi2, suggesting that none
of the cannabinoids evaluated exert their effects through Gαi2
signaling. Moreover, ACEA had no effect on Gαz. As previously
observed for the other two cannabinoid ligands evaluated,
ACEA also activated Gαq/11 subunit (122 ± 7%) while had no
effect on Gαs. Thus, it seems that none of these cannabinoid
ligands are able to activate this AC stimulatory subunit either.
No changes were observed when we studied the effects of
ACEA on the RhoA activator Gα12/13 subunit. Again, the
activation of these G protein subunits was blocked when
membranes were co-incubated with the cannabinoid antagonist
O-2050.
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FIGURE 3 | Effects of THC, WIN55212-2, and ACEA on G protein activation in mouse brain membranes. [35S]GTPγS scintillation proximity assays coupled
to immunoprecipitation with specific antibodies against different Gα subunits (Gαi1, Gαi2, Gαi3, Gαo, Gαz, Gαs, Gαq/11, and Gα12/13) in mouse brain cortical
membranes co-incubated with (A) THC (10 µM) (B) WIN55212-2 (10 µM), or (C) ACEA (10 µM) in the presence or absence of the antagonist O-2050 (10 µM). Data
are shown as percentage of [35S]GTPγS basal binding values obtained for each specific subunit. Bars represent mean ± SEM of four to six different experiments
carried out in triplicate. Asterisks highlight those normalized values of stimulation or inhibition of basal binding which are statistically different from 100% (Student’s
t-test; ∗p < 0.05).
Effects of the Cannabinoid Antagonist
O-2050 on G Protein Activation in Mouse
Brain Membrane Homogenates
O-2050 was initially synthesized and described as a neutral
CB1 receptor antagonist, however, there are some evidences
suggesting that is able to act as an inverse agonist or even as a
partial agonist (Wiley et al., 2011). For this reason, and in order
to validate O-2050 as a useful pharmacological tool to antagonize
the effect mediated by cannabinoid receptors, [35S]GTPγS SPAs
were performed in mouse cortical membranes in the presence
of O-2050 (10 µM) alone. Under these experimental conditions,
neither stimulation nor inhibition of [35S]GTPγS basal binding
values were observed for any of the Gα subunit subtypes studied,
with the exception of Gαz (119± 1%) (Figure 4).
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FIGURE 4 | Effects of the cannabinoid antagonist O-2050 on G protein
activation in mouse brain membranes. [35S]GTPγS scintillation proximity
assays coupled to immunoprecipitation with anti-Gαi1, Gαi3, Gαo, Gαz,
Gαq/11, and Gα12/13 specific antibodies in mouse brain cortical membranes
co-incubated with the cannabinoid antagonist O-2050 (10 µM). Data are
shown as percentage of [35S]GTPγS basal binding values obtained for each
specific subunit. Bars represent mean ± SEM of four to six different
experiments carried out in triplicate. Asterisks highlight those normalized
values of stimulation or inhibition of basal binding which are statistically
different from 100% (Student’s t-test; ∗p < 0.05).
Effects of 19-THC, WIN55212-2, and
ACEA on G Protein Activation in
Cannabinoid Receptors Knockout Mice
To further elucidate the role of each cannabinoid receptor
subtype in the agonist-mediated activation of the different
Gα subunit subtypes, [35S]GTPγS SPA was performed in
brain tissue of CB1−/−, CB2−/−, and CB1−/−/CB2−/− mice.
For that purpose, brain membranes were incubated with the
different cannabinoid ligands (THC, WIN55212-2, or ACEA)
and with the specific antibodies against that Gα for which
an stimulation with these agonists was observed in WT.
Figure 5A shows the stimulation of the different Gα subunits
when brain membranes of the four genotypes were incubated
with 19-THC. The significant stimulation of the inhibitory
Gαi1 subunit observed in the WT mice was completely
absent in the CB1−/− and in the CB1/CB2 double ko mice,
but was still present in the CB2−/− (108 ± 2%), which
suggests that the 19-THC-mediated stimulation of Gαi1 is
induced by the activation of CB1 receptor. On the other
hand, opposite results were obtained for Gαio and Gαz, the
other two inhibitory subunits that were stimulated by 19-
THC. As previously described, there was a significant 19-THC-
induced stimulation of Gαo and Gαz subunits in the WT.
This stimulation was also observed in the CB1−/− (115 ± 4%
for Gαo and 120 ± 4% for Gαz) but not in the CB2−/−
or the CB1−/−/CB2−/− mice. These data may indicate that,
in mouse brain cortical membranes, 19-THC acts through
the CB2 receptor to stimulate these inhibitory Gαo and Gαz
subunits. Finally, the 19-THC-induced activation of the Gαq/11
subunit observed in the WT mice was not found in the
CB1−/− and CB1−/−/CB2−/− mice, while remained unchanged
in the CB2−/− (116 ± 2%). This result indicates that 19-THC
stimulates the Gαq/11 subunit acting mainly through the CB1
receptor.
Figure 5B shows the stimulation of different Gα subunits
when brain membranes of the four genotypes were incubated
with the synthetic cannabinoid agonist WIN55212-2. The
significant stimulation of the inhibitory Gαi1 and Gαi3 subunits
induced by WIN55212-2 in the WT mice was not found in
the CB1−/− nor in the CB1−/−/CB2−/− mice, but was still
present in the CB2−/− (124 ± 5% for Gαi1 and 123 ± 5% for
Gαi3). On the contrary, the inhibitory subunits Gαo and Gαz,
which were significantly stimulated in the WT mice, remained
stimulated in the CB1−/− (111 ± 2% for Gαo and 123 ± 7% for
Gαz) but not stimulation was found in the CB2−/− nor in the
CB1−/−/CB2−/− mice. These results suggest that the inhibitory
signaling of WIN55212-2 in the mice brain through Gαi1 and
Gαi3 activation seems to be mediated by the CB1 receptor,
while the stimulation of Gαo and Gαz would be mediated by
the CB2 receptor activation. The significant activation of the
Gαq/11 subunit induced by WIN55212-2 in the WT mice was
completely absent in the CB1−/− mice, as well as in the CB1/CB2
double ko mice. On the contrary, a significant stimulation
of Gαq/11 subunit (120 ± 5%) was observed in the CB2−/−
membranes, suggesting that this stimulation is mediated by
the CB1 receptor. Strikingly, the observed stimulation of the
RhoA activator subunit Gα12/13 by WIN55212-2 in the WT
disappeared in the absence of CB2 receptor (both in CB2−/−
and CB1−/−/CB2−/− mice) suggesting an important role of this
CB2 receptor in the intracellular signaling through Gα12/13 in the
brain.
Finally, the same experiments were performed incubating
the brain membranes with the synthetic anandamide analog
ACEA (Figure 5C). Surprisingly, the significant stimulation
of Gαi1 that was observed in the WT mice was still found
in all the genotypes evaluated. These results suggest that
the inhibitory effect of ACEA mediated by the Gαi1 subunit
activation may be independent of cannabinoid receptors. On the
other hand, the significant stimulation of Gαi3 subunit induced
by ACEA was not observed in brain membranes of CB1−/−
mice but was still significant in CB2−/− membranes (111± 3%).
No stimulation was observed in the CB1−/−/CB2−/− mice.
Regarding the Gαo subunit, there was a significant stimulation
in the absence of CB1 receptors (115 ± 1%), while this
stimulation was not observed in the brain membranes of
CB2−/− mice, suggesting the necessary role of this receptor
in the activation of Gαo induced by the agonist ACEA.
The activation of the Gαq/11 subunit was observed in both
CB1−/− (117 ± 2%) and CB2−/− (118 ± 4%) but not in the
CB1−/−/CB2−/− mice. Thus, as for 19-THC and WIN55212-
2, the activation of Gαi3 and Gαo subunits was mediated by
their interaction with CB1 and CB2 receptors, respectively.
However, the stimulation of [35S]GTPγS binding to Gαq/11
subunit seems to be triggered by the activation of both CB1 and
CB2 cannabinoid receptors.
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FIGURE 5 | Effects of THC, WIN55, 212-2, and ACEA on G protein activation in cannabinoid receptors knockout mice. [35S]GTPγS scintillation proximity
assays coupled to immunoprecipitation with specific antibodies against different Gα subunits in mouse brain cortical membranes of WT, CB1 knockout (CB1−/−),
CB2 knockout (CB2−/−) and double CB1 and CB2 knockout (CB1−/−/CB2−/−/double KO) co-incubated with (A) THC (10 µM) (B) WIN55212-2 (10 µM), or (C)
ACEA (10 µM). Data are shown as percentage of [35S]GTPγS basal binding values obtained for each specific subunit. Bars represent mean ± SEM of four to six
different experiments carried out in triplicate. Asterisks highlight those normalized values of stimulation or inhibition of basal binding which are statistically different
from 100% (Student’s t-test; ∗p < 0.05).
Expression of G Protein Subunits in
Knockout Mice for Cannabinoid
Receptors
In order to determine if a physiological adaptation of knockout
mice to the genetic manipulation to inactivate CB1 and/or CB2
receptors may influence our results by the alteration of the
expression level of the different Gα protein subunits, Western
blotting assays were carried out in brain cortex membranes of
WT, CB1−/−, CB2−/−, and CB1−/−/CB2−/− mice.
In the case of Gαi1 (Figure 6A), no changes were observed
for CB1−/− and CB2−/−, but a significant reduction (33 ± 10%
from WT) of immunodensity was detected in CB1−/−/CB2−/−
mice brain membrane homogenates. No significant differences
were found in the expression of Gαo (Figure 6C) or Gα12/13
(Figure 6F) subunits between the WT, CB1−/−, CB2−/−, and
CB1−/−/CB2−/− mice brain membranes. However, an increase
in the expression of Gαi3 (Figure 6B) in both CB2−/− (139± 7%)
and CB1−/−/CB2−/− mice (140 ± 7%) was found when
compared to the WT and CB1−/− animals. On the contrary,
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FIGURE 6 | Expression of G protein subunits in cannabinoid receptors knockout mice. Immunoreactive signal and representative images obtained by
Western blotting with specific antibodies against different Gα subunits: (A) Gαi1, (B) Gαi3, (C) Gαo, (D) Gαz, (E) Gαq/11, and (F) Gα12/13 in mouse brain cortical
membranes of WT, CB1 knockout (CB1−/−), CB2 knockout (CB2−/−) and double CB1 and CB2 knockout (CB1−/−/CB2−/−/double KO). Immunoreactivity for
β-actin was simultaneously detected on every gel and used as loading control. Normalized values (percentage over controls) of Gα subunits are shown as
mean ± SEM of two different experiments carried out in duplicate. Asterisks highlight those values which are statistically different from WT (One-way ANOVA
followed by Dunnet’s post hoc test; ∗p < 0.05).
Gαz immunodensity was significantly increased in the CB1−/−
mice (129 ± 4%) while no changes were found in the rest of the
genotypes when comparing to the WT (Figure 6D). Finally, the
expression of Gαq/11 (Figure 6E) was significantly increased in
brain membranes of CB2−/− mice (137 ± 7%) but not in WT,
CB1−/− and CB1−/−/CB2−/− mice.
DISCUSSION
During the last years, a considerable effort has been made to
study the effects of cannabinoids in the brain trying to elucidate
the mechanisms by which these compounds may facilitate
mental disorders, such as addiction, cognitive deficits, anxiety or
psychosis. In this context, these studies have been performed with
different cannabinoid ligands (natural or synthetics), in cells or
in native tissue and/or in different animal species (mouse, rat,
human. . .).
There is wide evidence supporting the idea that for most of
GPCRs, distinct drugs are able to regulate different signaling
pathways by the selective activation of different intracellular
effectors. The pharmacological relevance of this fact is that the
biological responses not only depend on targeting a specific
GPCR but also on the particular pathway that this receptor
activates. Different studies have focused on the evaluation of
the functional selectivity of cannabinoid receptors, but most of
them have been performed in transfected cells expressing the
CB1 receptor (Glass and Northup, 1999; Bosier et al., 2010).
Moreover, much of these studies explore the signaling pathways
activated by different agonists by the evaluation of cAMP
production or the phoshorylation of intracellular mediators
such as ERK or AKT, with no data about the Gα subtype
responsible of these downstream effects. These changes on
cAMP concentration or ERK/AKT phosphorylation could be the
consequence of the activation of different Gα subtypes, Gβγ
dimmers, etc. On the other hand, and interestingly, opposite
behavioral effects have been observed after the administration
of 19-THC or synthetic cannabinoid ligands (Fattore et al.,
2003; Panagis et al., 2014; Rubino and Parolaro, 2016). For
example, when evaluating the cannabinoid effects on brain-
stimulation reward, Fattore et al. (2003) showed that the potent
non-selective CB1/CB2 receptor agonists WIN55,212-2 and CP
55,940, but not 19-THC, effectively restored heroin-seeking
behavior. In addition, it has been suggested that the signaling of
CB1 receptors may differ between humans and rodents (Straiker
et al., 2012).
All these frequently contradictory data highlight the relevance
of studying, simultaneously, the effects of different cannabinoid
ligands in the same tissue and under the same experimental
conditions.
For that reason the goal of the present study was to compare
the pattern of G protein subunit stimulation triggered by three
structurally different cannabinoids, 19-THC, WIN55212-2 and
ACEA in mouse brain cortex. To our knowledge, this is the
first study evaluating the cannabinoid-induced stimulation of the
different Gα subunits in mouse brain tissue.
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WIN55212-2, a synthetic cannabinoid structurally different
from 19-THC, is a potent, non-selective CB1/CB2 receptor
agonist that has been used in many studies of cannabinoid
receptor function (Pertwee et al., 2010). The synthetic
anandamide analog ACEA is a highly selective agonist for
the CB1 receptor with a low affinity for CB2 receptors (Hillard
et al., 1999).
This study demonstrates that each ligand displays functional
selectivity acting as biased agonist for a subset of different
G protein subunits. It represents the first characterization
of the activation of individual Gα subunits by endogenous
cannabinoid receptors in brain cortex. Firstly, we demonstrated
that phytocannabinoid 19-THC differs from the synthetic
agonists WIN55212-2 and ACEA in its ability to stimulate Gαi/o
protein subunits in brain cortex.
The Gαi subfamily members Gαi1, Gαi2, and Gαi3 were
originally identified by their ability to inhibit AC activity
(Plummer et al., 2012; Busnelli et al., 2013; Minetti et al.,
2014). Our results show that 19-THC, WIN55212-2, and
ACEA significantly stimulate Gαi1 subunit. Moreover, data from
knockout mice suggest that this effect may be CB1-mediated
in the case of 19-THC and WIN55 212-2. However, the Gαi1
stimulation is still significant in membranes of all genotypes
incubated with ACEA, suggesting that this is a non-CB1 non-
CB2 dependant effect and supporting putative actions of ACEA
over other receptors (Pertwee et al., 2010). Gαi3 subunit was
also stimulated in the presence of WIN55212-2 and ACEA,
but not of 19-THC. This stimulation seems to be mediated
by CB1 receptors as is blocked in the presence of O-2050
and absent in CB1−/− or CB1−/−/CB2−/− mice. In the case
of Gαi2, it has been previously described that WIN55212-2 is
able to activate this subunit in rat (Prather et al., 2000) and
in human brain cortical membranes (Erdozain et al., 2012).
However, none of the agonists in the present study stimulated
the Gαi2 subunit. This discrepancy may be due to inter-specie
and/or regional differences, suggesting that WIN55212-2 may
signal through different G protein pools in human and mouse
brain cortex.
These three Gαi subunits form the Gαi/o subfamily with
the neuronal α-subunit Gαo, which corresponds to the most
abundant Gα protein in brain (Sternweis and Robishaw, 1984).
In our experimental approach, and in accordance with other
studies (Glass and Northup, 1999; Presley et al., 2016), 19-THC,
WIN55212-2 and ACEA significantly stimulated Gαo. Results
obtained in knockout animals show that the stimulation of Gαo
in mouse cortex is mediated, at least in part, by CB2 receptors,
suggesting a necessary role of this receptor in the cannabinoid-
induced activation of Gαo.
The Gαz subtype is the most divergent member of the
inhibitory subfamily and is distributed primarily in neuronal
and neuroendocrine cells (Hinton et al., 1990). While 19-THC
and WIN55212-2, similarly, stimulated Gαz, no stimulation of
this subunit was observed when membranes were incubated
with ACEA, suggesting that ACEA may not signal through
this subunit. Additionally, results obtained with knockout mice
suggest that the stimulation of Gαz by19-THC and WIN55212-2
may be induced by a CB2-mediated mechanism.
Unlike Gαz, the Gαs family is ubiquitously expressed and
couples receptors to AC in a stimulatory fashion (Milligan
and Kostenis, 2006). Under the present assay conditions, nor
19-THC, WIN55212-2 or ACEA were able to activate this
stimulatory subunit. Thus, there is no evidence of Gαs coupling
of cannabinoid receptors in the presence of any of these drugs
in brain tissue. There are contradictory results about the ability
of cannabinoid drugs to activate Gαs proteins. In this way, there
are data from both CHO cell lines (Rinaldi-Carmona et al.,
1996; Bonhaus et al., 1998) and HEK cells (Presley et al., 2016)
expressing CB1 receptor, showing the absence of effect as well
as a modest but significant coupling of CB1 to Gαs triggered by
different cannabinoids. It has been proposed that ACEA may
elevate cAMP through a non-CB1 mechanism, since there is an
increase in cAMP in both cells transfected and non-transfected
with CB1 and pretreated with pertussis toxin (Presley et al., 2016).
It is important to point out that all these studies have been
performed in cell lines. Moreover, they use the accumulation of
cAMP in the presence of the Gαi/o inhibitor pertussis toxin as
an indirect evaluation of potential coupling of CB1 receptors to
Gαs. This increase in cAMP production can be mediated by a
mechanism different from Gαs activation, as they did not explore
directly the activation of this subunit. Therefore, the possible
increase in cAMP induced by other actors different from Gαs
subunits could not be discarded.
The Gαq/11 proteins, widely expressed through the CNS,
mediate PLC activation, leading to the activation of downstream
calcium signaling pathways including PKC and MAPKs
activation (Sanchez-Fernandez et al., 2014). In this study, a
significant stimulation of Gαq/11 was observed in the presence of
the three cannabinoids evaluated. It has been previously reported
that WIN55212-2 induces the coupling of CB1 to Gαq/11 in
different cellular types (Lauckner et al., 2005; McIntosh et al.,
2007). Our results show that not only WIN55212-2 but also
19-THC and ACEA can activate Gαq/11 subunit in mouse brain.
Moreover, the activation of this subunit induced by 19-THC
and WIN55212-2 seem to be mediated by the CB1 receptor, as
demonstrate the data obtained with knockout animals. In the
case of ACEA, our data suggest that ACEA modulate Gαq/11
through both CB1 and CB2 cannabinoid receptors.
The Gα12/13 proteins regulate important signaling events by
the activation of the small GTPase protein RhoA, involved in
the regulation of the actin cytoskeleton and cell motility (Kozasa
et al., 2011; Yu and Brown, 2015). Under our experimental
conditions, a significant stimulation of Gα12/13 subunit was
observed when membranes were incubated with WIN55212-
2 but not with 19-THC or ACEA. To our knowledge, this
is the first study reporting that WIN55212-2 signals through
Gα12/13 in brain cortex. These data are concordant with other
studies suggesting that cannabinoids induce the stimulation
of this RhoA-activator (Dalton et al., 2013; Roland et al.,
2014). Moreover, our results from knockout mice show that the
WIN55212-2-induced signaling through Gα12/13 in the brain
seems to be mediated, mainly, by the CB2 receptor.
Although O-2050 had been described as a CB1 antagonist,
it displays a complex pharmacological profile. In this context,
its good affinity for CB2 receptors complicates its use as a tool
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to evaluate the unique contribution of CB1 receptor (Wiley
et al., 2011). We observed that, when alone, O-2050 activated
the Gαz subunit. Therefore, in co-incubations, O-2050 behaved
always as an antagonist of the effects of 19-THC, WIN55212-
2 and ACEA over all the studied Gα subunit subtypes, except
for the Gαz subunit. When WIN55212-2 and O-2050 were co-
incubated, the stimulation of Gαz was lower but still significant.
In this way, the blockade exerted by O-2050 pharmacologically
confirmed the involvement of cannabinoid receptors in the
observed stimulations.
Studies in knockout mice provide very valuable data in basic
research but in addition to the absence of the targeted protein, we
cannot discard the appearance of putative neurodevelopmental
compensatory mechanisms. In this work, we have used CB1
and/or CB2 receptor knockout mice to elucidate the role of
each receptor in the observed effects of different ligands on the
stimulation of Gα subunits. Moreover, Western blotting assays
were carried out in order to unmask the role of a possible
adaptation of cannabinoid receptors knockout mice affecting the
expression level of the different Gα subtypes on the different
genotypes. The observed stimulations in knockout mice may
not be influenced by putative neurodevelopmental compensatory
mechanisms involving G proteins density. In this way, although
expression of some Gα subunits in knockout mice is different
from the WT, these changes do not explain the absence of
stimulation in CB1 or CB2 knockout mice. The convergence
of our pharmacological and genetic data demonstrate that the
results obtained herein with the cannabinoid receptors knockout
mice are likely due to the absence of the CB1 and/or CB2 receptors
and not to non-specific changes due to neurodevelopmental
adaptations.
CONCLUSION
Our results demonstrate that, in mouse brain native tissue
and under our experimental conditions different exogenous
cannabinoids are able to selectively activate different inhibitory
and non-inhibitory Gα protein subtypes, through the activation
of CB1 and/or CB2 receptors. However, it is important to be aware
of potential limitations. It has been suggested that the signaling of
CB1 receptors is significantly diminished in humans compared to
that of rodents, a finding that may have implications for the use
of rodent models for studies of CB1 receptor function related to
human disease and therapy (Straiker et al., 2012).
Results of the present study may help to dissect the specific
signaling pathways involved in the different pharmacological
actions of cannabinoids. Moreover, the knowledge of the specific
molecular target responsible of these different physiological
effects will help in the design of new biased cannabinoid drugs
with more specific therapeutic effect and a reduced range of
adverse effects.
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